We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.82B
AUM Growth
+$974M
Cap. Flow
+$85.6M
Cap. Flow %
0.97%
Top 10 Hldgs %
37.09%
Holding
149
New
20
Increased
26
Reduced
29
Closed
13

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$111M
2
AGN.PRA
Allergan plc
AGN.PRA
+$73.1M
3
MRK icon
Merck
MRK
+$69.9M
4
AET
Aetna Inc
AET
+$63.6M
5
VTRS icon
Viatris
VTRS
+$52.4M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$148M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.3M
3
AGN
Allergan plc
AGN
+$68.1M
4
ISRG icon
Intuitive Surgical
ISRG
+$67.6M
5
SHPG
Shire pic
SHPG
+$53.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.96%
2 Financials 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$450M 5.1%
3,710,986
+322,600
+10% +$41.6M
BIIB icon
2
Biogen
BIIB
$30.4B
$393M 4.45%
1,436,900
+155,700
+12% +$44M
CELG
3
DELISTED
Celgene Corp
CELG
$390M 4.42%
3,132,177
+25,400
+0.8% +$3.04M
BSX icon
4
Boston Scientific
BSX
$68.5B
$381M 4.32%
15,311,400
-1,195,500
-7% -$29.1M
MRK icon
5
Merck
MRK
$326B
$363M 4.12%
5,989,215
+1,152,485
+24% +$69.9M
LLY icon
6
Eli Lilly
LLY
$1.09T
$280M 3.18%
3,330,200
+591,200
+22% +$47.4M
WMGI
7
DELISTED
Wright Medical Group Inc
WMGI
$278M 3.16%
8,946,234
+1,361,900
+18% +$36.9M
INCY icon
8
Incyte
INCY
$26B
$264M 2.99%
1,973,597
-109,203
-5% -$13.9M
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$124B
$237M 2.69%
2,169,200
+9,800
+0.5% +$863K
AMGN icon
10
Amgen
AMGN
$212B
$236M 2.67%
1,438,300
-893,500
-38% -$148M
A icon
11
Agilent Technologies
A
$39.7B
$192M 2.18%
3,629,900
– –
PFE icon
12
Pfizer
PFE
$144B
$185M 2.1%
5,698,029
+251,062
+5% +$7.92M
EW icon
13
Edwards Lifesciences
EW
$48.2B
$173M 1.96%
5,517,900
+1,463,700
+36% +$45.8M
AET
14
DELISTED
Aetna Inc
AET
$167M 1.9%
1,312,400
+506,500
+63% +$63.6M
SHPG
15
DELISTED
Shire pic
SHPG
$156M 1.77%
897,451
-305,900
-25% -$53.4M
HCA icon
16
HCA Healthcare
HCA
$92.8B
$155M 1.76%
1,745,000
-257,200
-13% -$21.4M
HUM icon
17
Humana
HUM
$46.7B
$153M 1.73%
742,300
-94,100
-11% -$19.5M
REGN icon
18
Regeneron Pharmaceuticals
REGN
$72.9B
$147M 1.66%
378,170
+22,870
+6% +$8.48M
ELV icon
19
Elevance Health
ELV
$83.7B
$143M 1.62%
862,600
-159,000
-16% -$25.3M
ABBV icon
20
AbbVie
ABBV
$465B
$136M 1.54%
2,080,000
-845,000
-29% -$53.1M
ARRY
21
DELISTED
Array Biopharma Inc
ARRY
$127M 1.44%
14,182,900
-1,905,900
-12% -$20.3M
IRWD icon
22
Ironwood Pharmaceuticals
IRWD
$626M
$124M 1.4%
8,646,112
– –
CNC icon
23
Centene
CNC
$31.6B
$118M 1.34%
+3,311,400
New +$111M
ICPT
24
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$117M 1.33%
1,037,000
-83,000
-7% -$9.69M
AGN
25
DELISTED
Allergan plc
AGN
$114M 1.29%
477,390
-292,300
-38% -$68.1M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2017 Portfolio in Review

As of Q1 2017, OrbiMed held 149 positions worth $8.82B, up 12% from $7.85B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q1 2017 filing shows 20 new, 26 increased, 29 reduced and 13 closed positions. Its largest new stake was Centene: 3,311,400 shares worth $118M. The largest sale was Amgen, an estimated $148M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2017 buy was Centene: 3,311,400 shares worth $118M.
  • OrbiMed added most to Merck in Q1 2017, an estimated $69.9M increase.
  • OrbiMed's biggest Q1 2017 reduction was Amgen, cutting an estimated $148M.
  • OrbiMed fully exited Molina Healthcare in Q1 2017, selling an estimated $26.9M.
  • OrbiMed's ten largest holdings make up 37% of its $8.82B portfolio in Q1 2017.
  • OrbiMed opened 20 new positions and closed 13 in Q1 2017.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $8.82B.

Based on OrbiMed's 13F filing for Q1 2017, filed 15 May 2017.